Metronidazole suspension pharmacokinetics
Pro Research Analysisby 
Searched over 200M research papers
Metronidazole Suspension Pharmacokinetics: Absorption, Distribution, and Elimination
Oral Suspension Absorption and Systemic Availability
Metronidazole suspensions, including those formulated from benzoylmetronidazole, show effective absorption into the systemic circulation. After oral administration of benzoylmetronidazole suspension (equivalent to 2 g or 400 mg metronidazole), peak plasma concentrations were reached at 5.1 hours (17 µg/ml) and 3.2 hours (4.6 µg/ml), respectively. In comparison, a direct oral dose of metronidazole (400 mg) resulted in a peak plasma concentration of 8.5 µg/ml at 0.8 hours. The systemic availability of metronidazole from benzoylmetronidazole suspension is about 80% of that from direct metronidazole, and this availability is consistent across the studied dose range. These findings suggest that oral liquid formulations of metronidazole can maintain therapeutic plasma concentrations throughout a once-daily dosing interval, making them a suitable alternative to other forms of the drug .
Pharmacokinetic Parameters: Half-life, Clearance, and Steady-State
The elimination half-life of metronidazole after oral administration is generally between 7 and 8.7 hours in healthy adults, with no significant difference between oral and intravenous routes. Renal clearance is low (about 10.2 ml/min per 1.73 m²), and less than 20% of the administered dose is recovered in urine as active drug within 24 hours. With repeated dosing, blood levels increase initially but stabilize without significant accumulation after several days. Minimum serum concentrations remain above the inhibitory levels for most anaerobic bacteria, supporting the effectiveness of standard dosing regimens Ralph1974Houghton1979.
Pediatric and Neonatal Pharmacokinetics
In pediatric patients, especially those with acute appendicitis, once-daily dosing of metronidazole suspension (30 mg/kg) achieves target drug exposure (AUC/MIC ratio ≥70) for Bacteroides fragilis with an MIC of 2 mcg/mL or less. This exposure is similar to that seen in adults receiving standard dosing, and more frequent dosing does not provide additional pharmacokinetic or pharmacodynamic benefit in this population . In preterm and term infants, population pharmacokinetic models validated with dried blood spot sampling support existing dosing guidelines and suggest a 6-hour dosing interval for infants with postmenstrual age over 40 weeks, ensuring safe and effective drug exposure .
Special Populations: Diabetes and Animal Models
In patients with type II diabetes, metronidazole pharmacokinetics are altered: maximum serum concentration and elimination rate are decreased, while time to peak, area under the curve, and half-life are increased compared to healthy individuals. This suggests that diabetes can affect drug absorption and elimination, potentially requiring dose adjustments . In animal studies, such as in sea turtles and small ruminants, metronidazole shows high bioavailability and similar pharmacokinetic profiles across species, though clearance rates may vary, highlighting the need for species-specific dosing Norton2024Fadel2024.
Stability of Metronidazole Suspensions
Metronidazole suspensions prepared from USP-grade powder or commercial tablets remain stable for up to 90 days when stored properly, maintaining drug concentration and physical properties. This supports the use of extemporaneously prepared suspensions as a reliable alternative for patients who require liquid formulations .
Conclusion
Metronidazole suspension demonstrates reliable absorption, predictable pharmacokinetics, and effective systemic availability in both adults and children. Once-daily dosing is generally sufficient to maintain therapeutic levels, and the drug remains stable in compounded suspensions. Special populations, such as diabetic patients and neonates, may require tailored dosing based on altered pharmacokinetic profiles. Overall, metronidazole suspension is a practical and effective formulation for a wide range of patients Houghton1982Ralph1974Houghton1979+4 MORE.
Sources and full results
Most relevant research papers on this topic